Swiss Longitudinal Cohort

• Sponsor: Hypertension Excellence Centre Lucerne (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT02282748
• Collaborator: (none)
• Enrollment: 1,000
• Locations: 3
• Duration (Months): 239
• Patients Per Site: 333.3
• Patients Per Site Per Month: 1.4

Study Details

Study Description

Brief Summary

The planned research project is a prospective population-based cohort study, similar to the well-known Framingham study in the United States. So far, there is no similar research project in Switzerland.

It is planned to examine of three Swiss municipalities. Recruitment in a first Swiss municipality (Lostallo/Cama GR) started 2014 and ended in 2019. Overall, 496 participants were recruited in this municipality. The five-year follow-up in this municipality started in 2019. It is planned to start recruitment in a second Swiss municipality (Uznach SG) in 2020.

The examinations embrace a broad spectrum of measurements (for details the investigators refer to the published study protocol).

Condition or Disease	Intervention/Treatment	Phase
Cardiovascular Risk Factors	Other: No intervention

Study Design

• Study Type: Observational
• Anticipated Enrollment: 1000 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Swiss Longitudinal Cohort
• Study Start Date: Oct 1, 2014
• Anticipated Primary Completion Date: Sep 1, 2024
• Anticipated Study Completion Date: Sep 1, 2034

Outcome Measures

Primary Outcome Measures

1. Mortality [10 years]

Secondary Outcome Measures

1. Cardiovascular events [10 years]

   Cardiovascular events (i.e. stroke, myocardial infarction) will be assessed using questionnaires and case records.

2. Heart function [10 years]

   Heart function will be assessed using questionnaires for symptoms, clinical examination and measurement of electromechanical activation time.

3. Cognitive function [10 years]

   Cognitive function will be assessed using validated instruments.

4. Kidney function [10 years]

   Kidney function will be assessed using laboratory measurements.

5. Autonomy [10 years]

   Autonomy wil be assessed using validated instruments.

6. Nursing home admission [10 years]

   Nursing home admissions will be assessed using standardized questions.

Other Outcome Measures

1. Changes in cardiovascular risk factors [10 years]

   Cardiovascular risk factors will be assessed using validated measurements.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 6 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Resident of Cama GR, Lostallo GR, or Uznach SG

• Age ≥6 years (no upper age limit), for voluntary blood sample ≥18 years

• Willing to participate in long-term study

• Written informed consent (in participants ≥6 years and <18 years signed by parents)

Exclusion Criteria:

• No exclusion criteria

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cama	Cama	Graubünden	Switzerland	CH-6557
2	Lostallo	Lostallo	Graubünden	Switzerland	CH-6558
3	Linth Hospital	Uznach	Saint Gallen	Switzerland	8730

Sponsors and Collaborators

• Hypertension Excellence Centre Lucerne

Investigators

• Study Chair: Paul Erne, MD, Hypertension Excellence Centre Lucerne
• Principal Investigator: Andreas W Schoenenberger, MD, University Department of Geriatrics, University of Bern
• Principal Investigator: Paolo Suter, MD, University of Zurich
• Principal Investigator: Franco Muggli, MD, Swiss Society of Hypertension
• Principal Investigator: Renate Schoenenberger, MD, Hypertension Excellence Centre Lucerne
• Principal Investigator: Pierre-Alexandre Krayenbühl, MD, Linth Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hypertension Excellence Centre Lucerne
• ClinicalTrials.gov Identifier: NCT02282748
• Other Study ID Numbers: SNCTP 000000612
• First Posted: Nov 4, 2014
• Last Update Posted: Feb 18, 2020
• Last Verified: Feb 1, 2020

Study Results

No Results Posted as of Feb 18, 2020